Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

Cheng-Lung Hsu(Chang Gung University), Hsin-Pai Li(Chang Gung University of Science and Technology), Yung‐Chia Kuo(Linkou Chang Gung Memorial Hospital), Alex Y. Chang(Cornell University), Yuan‐Ming Yeh(Chang Gung Memorial Hospital), Li‐Yu Lee(Chang Gung University), Yin‐Kai Chao(Chang Gung University), Yu‐Sun Chang(Chang Gung University), Yen-Jung Lu(Genomics Research Center, Academia Sinica), Mei-Yuan Huang(Chang Gung University), An-Chi Lin(Chang Gung University), Ngan‐Ming Tsang, Hsien-Chi Fan(Chang Gung University), Chun‐Nan Yeh(Chang Gung University), Lang-Ming Chi(Chang Gung Memorial Hospital), Yenlin Huang(Chang Gung University), Kar‐Wai Lui, Chia-Hsun Hsieh(Chang Gung Memorial Hospital), Hung-Ming Wang(Chang Gung University), Yi-Ru Lai(Chang Gung University), Tung‐Liang Lin(Chang Gung University), Kai‐Ping Chang(Chang Gung University)
Journal of Experimental & Clinical Cancer Research
September 20, 2018
10.1186/s13046-018-0873-5
Cited by 36

Related Papers

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
|The Lancet|2005|2.1k
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2006|705
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
|Journal of Clinical Oncology|2018|473
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
|Lung Cancer|2010|441
Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia
|Science Translational Medicine|2017|381